| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3198856 | Journal of Allergy and Clinical Immunology | 2011 | 8 Pages |
Abstract
This study demonstrated that a fixed dose of 300 or 600 mg of omalizumab provides rapid and effective treatment of CIU in patients who are symptomatic despite treatment with H1-antihistamines.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Sarbjit MD, Karin E. MD, PhD, Hsin-Ju PhD, Dennis A. MD, Edward MD, Allen MD, Sheldon MD, Marcus MD,